Clinical Cancer Research, Vol 3, Issue 8 1277-1288, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

MR Albertini, JA Hank, JH Schiller, M Khorsand, AA Borchert, J Gan, R Bechhofer, B Storer, RA Reisfeld and PM Sondel
University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, Madison, Wisconsin 53792, USA.

We conducted a Phase IB trial of antidisialoganglioside chimeric 14. 18 (ch14.18) antibody and interleukin 2 (IL-2) to determine the maximal tolerated dose (MTD), immunological effects, antitumor effects, and toxicity of this treatment combination. Twenty-four melanoma patients received immunotherapy with ch14.18 antibody and a continuous infusion of Roche IL-2 (1.5 x 10(6) units/m2/day) given 4 days/week for 3 weeks. The ch14.18 antibody (dose level, 2-10 mg/m2/day) was scheduled to be given for 5 days, before, during, or following initial systemic IL-2 treatment. The ch14.18 MTD was 7.5 mg/m2/day, and 15 patients were treated with the ch14.18 MTD. Immunological effects included the induction of lymphokine-activated killer activity and antibody-dependent cellular cytotoxicity by peripheral blood mononuclear cells. In addition, serum samples obtained following ch14.18 infusions were able to facilitate in vitro antibody-dependent cellular cytotoxicity. Antitumor activity included one complete response, one partial response, eight patients with stable disease, and one patient with >50% decrease of hepatic metastases in the face of recurrence of a s.c. lesion. Dose-limiting toxicities were a severe allergic reaction and weakness, pericardial effusion, and decreased performance status. Most patients treated at the MTD had abdominal, chest, or extremity pain requiring i.v. morphine. One patient had an objective peripheral neuropathy. This IL-2 and ch14.18 treatment combination induces immune activation in all patients and antitumor activity in some melanoma patients. We are attempting to enhance this treatment approach by addition of the anti-GD3 R24 antibody to this IL-2 and ch14.18 regimen.

This article has been cited by other articles:

				K. L. Osenga, J. A. Hank, M. R. Albertini, J. Gan, A. G. Sternberg, J. Eickhoff, R. C. Seeger, K. K. Matthay, C. P. Reynolds, C. Twist, et al. A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group. Clin. Cancer Res., March 15, 2006; 12(6): 1750 - 1759. [Abstract] [Full Text] [PDF]

				M. Imai, C. Landen, R. Ohta, N.-K. V. Cheung, and S. Tomlinson Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer Cancer Res., November 15, 2005; 65(22): 10562 - 10568. [Abstract] [Full Text] [PDF]

				E. Bolesta, A. Kowalczyk, A. Wierzbicki, P. Rotkiewicz, B. Bambach, C.-Y. Tsao, I. Horwacik, A. Kolinski, H. Rokita, M. Brecher, et al. DNA Vaccine Expressing the Mimotope of GD2 Ganglioside Induces Protective GD2 Cross-reactive Antibody Responses Cancer Res., April 15, 2005; 65(8): 3410 - 3418. [Abstract] [Full Text] [PDF]

				D. M. King, M. R. Albertini, H. Schalch, J. A. Hank, J. Gan, J. Surfus, D. Mahvi, J. H. Schiller, T. Warner, K. Kim, et al. Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients J. Clin. Oncol., November 15, 2004; 22(22): 4463 - 4473. [Abstract] [Full Text] [PDF]

				P. B. Chapman T-Cell Chauvinists Versus Antibody Advocates--Can't We All Just Get Along? J. Clin. Oncol., November 15, 2004; 22(22): 4446 - 4448. [Full Text] [PDF]

				M. F. Ozkaynak, P. M. Sondel, M. D. Krailo, J. Gan, B. Javorsky, R. A. Reisfeld, K. K. Matthay, G. H. Reaman, and R. C. Seeger Phase I Study of Chimeric Human/Murine Anti-Ganglioside GD2 Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children's Cancer Group Study J. Clin. Oncol., December 15, 2000; 18(24): 4077 - 4085. [Abstract] [Full Text] [PDF]

				J. A. Hank, J. Surfus, J. Gan, M. Albertini, M. Lindstrom, J. H. Schiller, K. M. Hotton, M. Khorsand, and P. M. Sondel Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations Clin. Cancer Res., February 1, 1999; 5(2): 281 - 289. [Abstract] [Full Text] [PDF]